Scarica l'app Stockscreener
2.88
0.69%
-0.02
Pre-mercato:
2.88
Precedente Chiudi:
$2.90
Aprire:
$2.95
Volume 24 ore:
70,468
Relative Volume:
0.17
Capitalizzazione di mercato:
$10.17M
Reddito:
-
Utile/perdita netta:
$2.81M
Rapporto P/E:
-0.2007
EPS:
-14.3497
Flusso di cassa netto:
$7.14M
1 W Prestazione:
-7.99%
1M Prestazione:
-3.36%
6M Prestazione:
-12.73%
1 anno Prestazione:
-31.43%
Intervallo 1D:
$2.6902
$2.99
Intervallo di 1 settimana:
$2.6902
$3.17
Portata 52W:
$2.51
$4.86
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Nome
Kiora Pharmaceuticals Inc
Settore
Industria
Telefono
781-788-8869
Indirizzo
332 ENCINITAS BOULEVARD, ENCINITAS
Confronta KPRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.88 | 10.17M | 0 | 2.81M | 7.14M | -14.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Kiora Pharmaceuticals Inc Borsa (KPRX) Ultime notizie
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 0.3% – Here’s Why - Defense World
Kiora Pharmaceuticals and Senju Pharmaceutical partner on KIO-301 for retinal disease treatment in Asia - Ophthalmology Times
kiora pharmaceuticals reports results of annual shareholder meeting By Investing.com - Investing.com South Africa
kiora pharmaceuticals reports results of annual shareholder meeting - Investing.com
Kiora Pharmaceuticals Holds Annual Meeting, Elects Directors - TipRanks
Oil Prices Climb While US Equity Futures Stutter - Finimize
MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V Lead $3 Undercard SurgeMore Stocks Inside! - openPR.com
Pre-market Movers: STSS, SGMT, NIVF, OGEN... - RTTNews
MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V Lead $3 Undercard Surge – More Stocks Inside! - FinancialContent
Kiora Pharmaceuticals inks potential $110 million deal with Senju By Investing.com - Investing.com South Africa
ReShape Lifesciences And Kiora Pharma Impress Investors, Dollar General Uplifts Outlook - Finimize
Sector Update: Health Care - marketscreener.com
Kiora Pharmaceuticals Stock Skyrockets Over 20% in Dynamic Trading Session - Daily Chhattisgarh News
Traws Pharma Inc. Stock Skyrockets Over 40%, Then Pares Gains in Volatile Trading - Daily Chhattisgarh News
Pre-market Movers: NIVF, TRAW, KKR, AGEN... - RTTNews
Kiora PharmaceuticalsEnters Exclusive Option Agreement With SenjuSEC Filing - marketscreener.com
Kiora Pharmaceuticals inks potential $110 million deal with Senju - Investing.com
Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-30 - GuruFocus
Kiora Pharmaceuticals Lands $110M Asian Partnership Deal for Revolutionary Retinal Disease Treatment - Stock Titan
Kiora Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Arrowhead (ARWR) Skyrockets Over 5.7%: Can This Biotech Breakout Propel It Towards $20? - Daily Chhattisgarh News
Q1 Earnings Estimate for KPRX Issued By HC Wainwright - Defense World
Pre-market Movers: HCTI, PTIX, BCLI, AFMD... - RTTNews
Northern Trust Strengthens Canadian Leadership: Industry Veteran Jeff Alexander Takes Helm of 150-Client Operation - Stock Titan
Persistent Epithelial Defect Market on Track for Major - openPR.com
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Kiora Pharmaceuticals Reports First Quarter Results; Initiating - GuruFocus
Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 | KPRX - GuruFocus
Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027 - Stock Titan
Kiora Pharmaceuticals Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy | KPRX Stock News - GuruFocus
Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy - Newsfile
May 2025 Penny Stocks With Promising Potential - simplywall.st
Kiora Pharmaceuticals (KPRX) Projected to Post Quarterly Earnings on Friday - Defense World
Top Penny Stocks To Watch In May 2025 - Yahoo Finance
Promising Penny Stocks To Consider In April 2025 - Yahoo Finance
KPRXKIORA PHARMACEUTICALS INC Latest Stock News & Market Updates - Stock Titan
Top Penny Stocks To Watch In April 2025 - Yahoo Finance
Corneal Epithelial Defect Therapeutics Market Size in 7MM - openPR.com
CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga
Metagenomi Leads The Charge With These 3 Penny Stocks - simplywall.st
Talkspace And 2 Other Promising Penny Stocks - Yahoo Finance
Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference - Newsfile
Kiora Unveils Latest Progress on Two Phase 2 Retinal Disease Treatments - Stock Titan
Adagene And 2 Other Promising Penny Stocks To Watch - simplywall.st
Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why - The Globe and Mail
Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks - Yahoo Finance
Kiora Pharmaceuticals (NASDAQ:KPRX) Earns “Buy” Rating from HC Wainwright - Defense World
Kiora Pharmaceuticals Advances Retinal Disease Pipeline - TipRanks
Kiora Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027 - TradingView
Kiora Pharmaceuticals Inc Azioni (KPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Kiora Pharmaceuticals Inc Azioni (KPRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shapiro Aron | Director |
Sep 10 '24 |
Buy |
3.60 |
3,000 |
10,800 |
3,000 |
| Walters-Hoffert Lisa | Director |
Aug 19 '24 |
Buy |
3.86 |
1,250 |
4,825 |
1,250 |
| TYLE PRAVEEN | Director |
Aug 19 '24 |
Buy |
3.96 |
5,000 |
19,800 |
5,014 |
| Tosca Melissa | CFO |
Aug 14 '24 |
Buy |
3.21 |
2,000 |
6,420 |
13,599 |
0.78%
0.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):